David Epstein, who previously served as the CEO of Seagen, has launched a new cancer startup called Ottimo Pharma. The company aims to develop a drug that targets two proteins, PD-1 and VEGF, in various types of cancers. This approach is gaining popularity in the field of immuno-oncology.
Epstein’s goal with Ottimo Pharma is to conduct a Phase 1 trial, potentially starting late next year. The data from this trial is expected to be promising and attract acquisition offers for the company. Ottimo Pharma will focus on cancer types like non-small cell lung cancer, where other similar drugs have shown effectiveness, as well as other types of cancer that may be appealing to potential buyers.
This move comes shortly after Pfizer’s acquisition of Seagen for $43 billion, showing Epstein’s quick return to the biopharma industry. The development of innovative drugs for cancer treatment is crucial, and Ottimo Pharma’s focus on targeting specific proteins could lead to significant advancements in the field.
In a time where cancer research and treatment are rapidly evolving, Epstein’s new venture highlights the importance of continuous innovation and perseverance in the fight against cancer. The potential success of Ottimo Pharma’s experimental antibody could pave the way for new treatment options and improved outcomes for cancer patients worldwide.
